Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (110,291)	$ (124,137)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	808	283
Research and development license expense	1,250	6,750
Stock-based compensation	13,940	13,229
Other	616	450
Changes in operating assets and liabilities:
Prepaid expenses and other assets	1,980	(1,530)
Accounts payable	(3,217)	16,000
Accrued expenses and other liabilities	(7,753)	12,179
Due to related party		(8)
Net cash used in operating activities	(102,667)	(76,784)
Cash flows from investing activities
Purchase of research and development license	(4,250)	(6,000)
Purchase of property, plant and equipment	(18,310)	(7,034)
Net cash used in investing activities	(22,560)	(13,034)
Cash flows from financing activities
Proceeds from Term Loan, net		29,978
Proceeds from issuance of common stock, net of sales commissions	11,640
Payment of shelf registration costs	(319)
Proceeds from common stock issuances under ESPP	253
Other	(1,144)
Net cash provided by financing activities	10,430	29,978
Net decrease in cash, cash equivalents and restricted cash	(114,797)	(59,840)
Cash, cash equivalents and restricted cash at the beginning of the period	151,740	251,253
Cash, cash equivalents and restricted cash at the end of the period	36,943	191,413
Cash and cash equivalents	34,306	188,785
Restricted cash	2,637	2,628
Supplemental disclosure of cash flow information:
Cash paid for interest	1,758	110
Supplemental disclosure of noncash investing and financing activities:
Property, plant and equipment in accounts payable and accrued expenses	3,366	6,658
Acquisition of property, plant and equipment funded by landlord		606
Deferred offering costs not yet paid	$ 40	204
Purchase of research and development license not yet paid		750
Build-to-suit lease liability		$ 26,607